New Perspectives: An Oral Multikinase Inhibitor in Patients with Advanced RCC  Bernard Escudier  European Urology Supplements  Volume 6, Issue 7, Pages 499-504 (March 2007) DOI: 10.1016/j.eursup.2007.01.020 Copyright © 2007 Terms and Conditions

Fig. 1 Sorafenib is active against both tumour cell and tumour vasculature. (MEK=mitogen extracellular kinase; ERK=extracellular signal-regulated kinase; VEGFR=vascular endothelial growth factor receptor; PDGFR=platelet-derived growth factor receptor; PLC=phospholipase C; PI3K=phosphatidylinositol 3-kinase.) European Urology Supplements 2007 6, 499-504DOI: (10.1016/j.eursup.2007.01.020) Copyright © 2007 Terms and Conditions

Fig. 2 TARGET study design. (RCC=renal cell carcinoma; ECOG PS=Eastern Cooperative Oncology Group Performance Status; MSKCC=Memorial Sloan-Kettering Cancer Centre; b.i.d.=twice daily; OS=overall survival; PFS=progression-free survival.) European Urology Supplements 2007 6, 499-504DOI: (10.1016/j.eursup.2007.01.020) Copyright © 2007 Terms and Conditions

Fig. 3 Sorafenib significantly doubled progression-free survival compared with placebo. European Urology Supplements 2007 6, 499-504DOI: (10.1016/j.eursup.2007.01.020) Copyright © 2007 Terms and Conditions

Fig. 4 Change in tumour size from baseline in patients treated with sorafenib and placebo. European Urology Supplements 2007 6, 499-504DOI: (10.1016/j.eursup.2007.01.020) Copyright © 2007 Terms and Conditions

Fig. 5 At the time of crossover, a trend towards improved median overall survival was observed in patients treated with sorafenib compared with placebo. European Urology Supplements 2007 6, 499-504DOI: (10.1016/j.eursup.2007.01.020) Copyright © 2007 Terms and Conditions